Phenylketonuria (PKU) Genetic Test: PAH Gene Mutations and Results

A phenylketonuria genetic test looks for pathogenic variants in the PAH gene, which provides instructions for phenylalanine hydroxylase. This enzyme converts the amino acid phenylalanine into tyrosine. When both PAH copies have reduced function, phenylalanine can rise in blood and brain, causing phenylalanine hydroxylase deficiency, including classic PKU and milder hyperphenylalaninemia. Genetic testing usually follows an abnormal newborn screen or elevated blood phenylalanine. It helps confirm the cause, distinguish PAH deficiency from other disorders, estimate the chance of response to certain medicines, and guide family testing. DNA results do not replace blood phenylalanine measurements, because treatment and monitoring depend on the biochemical level rather than the gene result alone. Two pathogenic or likely pathogenic PAH variants generally establish the molecular diagnosis when they are on opposite chromosome copies and fit the biochemical findings. One variant usually indicates carrier status. A negative or uncertain result may require deletion analysis, broader metabolic testing, or evaluation for tetrahydrobiopterin-related disorders.

• PKU genetic testing usually identifies two disease-causing PAH variants in an affected person.
• One pathogenic PAH variant generally means carrier status, not PKU.
• Blood phenylalanine—not genotype alone—determines whether treatment is needed and whether control is adequate.
• A PAH result may help predict sapropterin responsiveness, but a supervised response trial is often still necessary.
• No fasting is required for DNA testing; blood, saliva, or cheek-swab samples may be used.
• An abnormal newborn screen needs prompt confirmatory testing because early treatment protects brain development.

Table of Contents

• What the PAH Test Is Used For
• Why Genetic and Biochemical Testing Are Both Needed
• Who Should Have PAH Testing
• PAH Variants and Inheritance
• Laboratory Methods and Sample Requirements
• Interpreting Positive, Negative, Carrier, and VUS Results
• What Genotype Can and Cannot Predict
• Family Testing, Pregnancy, and Long-Term Follow-Up

What the PAH Test Is Used For

The PAH genetic test identifies the DNA changes responsible for most cases of phenylalanine hydroxylase deficiency. The condition includes a continuum from mild hyperphenylalaninemia to classic PKU. These labels reflect untreated phenylalanine levels and metabolic function, not completely separate diseases.

The test may be used to:

• confirm PAH deficiency after an abnormal newborn screen;
• investigate persistent elevated phenylalanine in a child or adult;
• distinguish PAH deficiency from defects in tetrahydrobiopterin production or recycling;
• identify the familial variants for carrier or prenatal testing;
• clarify recurrence risk for parents and relatives;
• support assessment of possible responsiveness to sapropterin or other phenotype-linked therapies; and
• resolve an uncertain diagnosis in someone treated since infancy.

The test does not measure today’s phenylalanine concentration. It also cannot show whether diet is adequately controlled, whether brain exposure has been low enough over time, or whether a person can safely stop treatment. Those questions require regular biochemical monitoring and clinical assessment.

PAH deficiency is one of the conditions commonly identified by newborn screening, but the first screen is primarily biochemical rather than a complete DNA test. A dried blood spot collected after birth measures phenylalanine, often with the phenylalanine-to-tyrosine ratio. An out-of-range result triggers confirmatory blood testing and rapid metabolic evaluation.

The older term “phenylketonuria” is still widely used. “PAH deficiency” is more precise because it includes mild forms that may not produce the classic urinary phenylketones associated with untreated severe disease.

Why Genetic and Biochemical Testing Are Both Needed

PAH testing answers why phenylalanine is elevated. Biochemical testing shows how much it is elevated and how it responds to treatment. Both forms of evidence are important.

Phenylalanine is an essential amino acid found in protein. The body cannot make it and must obtain it from food. PAH normally converts excess phenylalanine to tyrosine with help from the cofactor tetrahydrobiopterin, often abbreviated BH4. When PAH activity is low, phenylalanine accumulates and can interfere with brain development and function.

Untreated severe PAH deficiency can cause profound intellectual disability, seizures, movement abnormalities, behavioral problems, eczema, microcephaly, and reduced pigmentation. Newborn screening and early treatment prevent the classic severe outcome in most diagnosed infants.

Current clinical guidance generally supports lifelong treatment when untreated phenylalanine is above 360 micromoles per liter, approximately 6 milligrams per deciliter. Many programs aim to keep blood phenylalanine between about 120 and 360 micromoles per liter, although targets, age-specific practices, pregnancy targets, and sampling schedules may vary by guideline and treatment center.

A genetic result cannot replace these values. Two people with similar PAH variants may have different untreated phenylalanine levels, dietary tolerance, treatment response, and neurocognitive outcomes. Conversely, a person’s blood level may change with age, illness, protein intake, pregnancy, treatment adherence, medication, and catabolic stress even though the DNA result remains the same.

Elevated phenylalanine can also result from conditions that do not primarily involve PAH. Defects in BH4 synthesis or recycling can cause hyperphenylalaninemia plus neurotransmitter deficiency and may require treatment beyond a low-phenylalanine diet. Liver disease, prematurity, parenteral nutrition, and other metabolic disturbances can also affect results. This is why confirmatory testing may include pterins, dihydropteridine reductase activity, additional genes, and other biochemical studies.

Who Should Have PAH Testing

Most testing begins after newborn screening, but people can be evaluated at any age.

Newborns with elevated phenylalanine

An abnormal newborn screen should be treated as time-sensitive. The care team typically repeats quantitative plasma amino acids, reviews feeding and clinical status, and contacts a metabolic specialist. Molecular testing can confirm PAH deficiency and identify the variants, but treatment should not be delayed while waiting for a long DNA turnaround time if phenylalanine is clearly elevated.

A newborn may be asymptomatic. The purpose of screening is to begin treatment before neurologic injury becomes visible. Parents should understand that a positive screen is not yet a final diagnosis and that false-positive or transient elevations can occur.

Older children or adults

Testing may be considered for a person with unexplained hyperphenylalaninemia, intellectual disability with a suggestive history, neurologic symptoms, a sibling with PKU, or a childhood diagnosis that was never molecularly confirmed. Adults who were lost to follow-up may benefit from renewed biochemical and genetic evaluation because treatment recommendations and therapeutic options have changed.

Relatives and reproductive partners

Once both familial variants are known, relatives can receive targeted testing. Siblings, adult children, and reproductive partners may want carrier information. General autosomal recessive carrier screening principles apply, but testing the known PAH variants is usually more direct than relying on a broad panel.

Pregnancy planning

People with PAH deficiency need preconception metabolic care because high maternal phenylalanine is teratogenic even when the fetus does not have PKU. PAH testing can clarify the partner’s carrier status and fetal inheritance risk, but maternal blood phenylalanine control is the immediate health issue for every pregnancy.

Carrier couples may also request prenatal or preimplantation testing. The family’s exact variants should be documented before a pregnancy whenever possible.

PAH Variants and Inheritance

PAH deficiency is inherited in an autosomal recessive pattern. An affected person usually has two pathogenic or likely pathogenic PAH variants, one on each chromosome copy. The variants may be identical, called homozygous, or different, called compound heterozygous.

When both parents are carriers, each pregnancy has:

• a 25% chance of a child with PAH deficiency;
• a 50% chance of a carrier child; and
• a 25% chance of a child who inherited neither family variant.

The probabilities reset for every pregnancy and do not depend on fetal sex. An unaffected full sibling of a person with PAH deficiency has a 2 in 3 chance of being a carrier after affected status has been excluded.

PAH contains hundreds of known disease-causing variants. They include missense changes, nonsense variants, splice-site changes, small insertions and deletions, and less commonly exon-level deletions or duplications. Different variants leave different amounts of residual enzyme activity.

Some variants are strongly associated with classic PKU, while others more often produce mild hyperphenylalaninemia. In compound heterozygotes, the milder allele may influence the overall phenotype, but interactions are complex. Genotype-phenotype databases can provide estimates, not guarantees.

Carriers with one pathogenic PAH variant are generally healthy and do not require a low-phenylalanine diet. A carrier may have a mildly altered enzyme measurement in research settings, but classic PAH deficiency requires two relevant variants or another confirmed disease mechanism.

A child can rarely have one variant inherited from a parent and a second de novo variant. Other unusual findings include parental mosaicism, uniparental disomy, or a deletion not detected by routine sequencing. These mechanisms are uncommon but may explain an unexpected family pattern.

Laboratory Methods and Sample Requirements

The molecular test usually begins with sequence analysis of PAH. A blood sample is common, although many laboratories accept saliva or a cheek swab. No fasting is required, and dietary phenylalanine restriction does not change the DNA result.

Sequence analysis

Next-generation sequencing reads the protein-coding exons and nearby splice boundaries. It detects most single-nucleotide variants and small insertions or deletions. Sanger sequencing may confirm variants or test relatives for a known familial change.

Deletion and duplication analysis

If sequencing finds only one pathogenic variant in a person with convincing biochemical PAH deficiency, the laboratory may look for missing or extra exons. Methods include multiplex ligation-dependent probe amplification, quantitative PCR, microarray-based analysis, or validated read-depth algorithms.

Targeted variant testing

Relatives can be tested only for the known family variants. This is efficient and usually easier to interpret. It does not assess the entire gene, so it should not be substituted for full analysis when the family variants are unknown or when a person has independent biochemical findings.

Multigene hyperphenylalaninemia testing

A panel may include PAH plus genes involved in BH4 metabolism and other causes of elevated phenylalanine. This can be useful when biochemical studies are incomplete, the presentation is atypical, or the initial PAH test is negative. A multigene panel may reduce diagnostic delay, but it can also produce uncertain findings that require careful correlation.

Exome or genome sequencing

Broader sequencing is rarely the first test for a straightforward newborn-screen diagnosis, but it may help when biochemical findings persist and targeted testing is unrevealing. Genome sequencing may detect deep intronic or structural changes missed by standard assays, although interpretation remains difficult.

Turnaround time commonly ranges from two to six weeks. Urgent newborn testing may be faster. The clinical team should begin appropriate biochemical management based on phenylalanine levels rather than waiting for final molecular confirmation.

Interpreting Positive, Negative, Carrier, and VUS Results

The report should be read together with plasma phenylalanine, tyrosine, the newborn-screen pattern, and any BH4-related studies.

Finding	Usual meaning	Common next step
Two pathogenic or likely pathogenic PAH variants	Supports PAH deficiency when variants are on opposite chromosome copies and biochemical findings match	Confirm phase if needed, continue metabolic management, and offer family testing
One pathogenic PAH variant	Usually carrier status; incomplete molecular diagnosis if phenylalanine is elevated	Add deletion/duplication analysis, review coverage, and evaluate other causes
No pathogenic PAH variant	PAH deficiency becomes less likely but may not be excluded	Check technical limits and test BH4-related or other genes
One or more PAH variants of uncertain significance	Evidence is insufficient to confirm or exclude disease	Use biochemical findings, family studies, functional data, and periodic reinterpretation

Positive affected result

Two pathogenic or likely pathogenic variants generally confirm the molecular cause. Parental testing can show that the variants are in trans, meaning one was inherited from each parent. If both variants are in cis on the same chromosome copy, the other PAH copy may be normal, and the person may be a carrier rather than affected.

A positive result should not be used to relax biochemical monitoring. Even a genotype usually associated with mild disease can produce clinically important phenylalanine levels. Treatment decisions should follow measured values and specialist guidance.

Carrier result

One pathogenic variant in a person with normal phenylalanine usually means carrier status. The reproductive partner can receive full PAH carrier testing or targeted testing according to the clinical context. If the partner tests negative, the chance of an affected child becomes low but is not zero because of residual risk.

Negative result

A negative PAH test is most reassuring when sequencing and deletion/duplication analysis were comprehensive and phenylalanine was normal. In a person with repeated hyperphenylalaninemia, a negative result needs further investigation rather than simple dismissal.

Variant of uncertain significance

A VUS is not diagnostic. It should not be used by itself to start lifelong dietary treatment, stop treatment, label a relative as a carrier, or make a fetal diagnosis. Biochemical data may provide strong evidence, but formal classification requires the laboratory’s accepted framework. The general rules for a VUS genetic test result apply.

What Genotype Can and Cannot Predict

PAH genotype can provide useful estimates of untreated metabolic severity. Variants associated with little or no enzyme activity often correspond to classic PKU, while variants with greater residual activity may correspond to milder hyperphenylalaninemia. This information can help clinicians anticipate dietary tolerance and discuss treatment possibilities.

Genotype may also suggest whether a person could respond to sapropterin, a pharmaceutical form of BH4 that can increase residual PAH activity in responsive individuals. Certain variants are more often responsive, while two clearly null variants make response less likely. However, genotype is not a perfect predictor. A supervised loading or response trial with repeated phenylalanine measurements may still be needed.

The genetic result may help explain why two siblings differ less or more than expected, but it cannot reliably predict:

• exact intellectual or executive-function outcomes;
• attention, anxiety, depression, or quality of life;
• the amount of natural protein tolerated at every age;
• long-term adherence to dietary treatment;
• the phenylalanine rise during illness or pregnancy;
• response to every medication; or
• the exact timing of future treatment changes.

Treatment options may include a phenylalanine-restricted diet, medical formula or amino-acid mixture, low-protein specialty foods, large neutral amino acids in selected adults, sapropterin, enzyme substitution therapy with pegvaliase for eligible adults, and newer pharmacologic approaches where approved. Availability and indications differ by country and continue to evolve.

Blood phenylalanine remains the practical outcome measure. Home dried-blood-spot collection is common, but the frequency of testing depends on age, treatment stability, pregnancy, and the treatment center. A DNA result does not expire, while management must adapt throughout life.

Family Testing, Pregnancy, and Long-Term Follow-Up

A confirmed molecular diagnosis allows accurate targeted testing in relatives. Parents are usually carriers, and adult siblings can learn their status before having children. Testing minors solely for carrier status may be deferred when it has no childhood medical benefit, but siblings should have newborn-screen records reviewed and be tested promptly if affected status is uncertain.

Carrier couples can consider natural conception with prenatal diagnosis, in vitro fertilization with preimplantation genetic testing, donor egg or sperm, donor embryo, adoption, or conception without fetal testing. Prenatal genetic diagnosis may use chorionic villus sampling or amniocentesis to test the known familial PAH variants.

Maternal PAH deficiency

A pregnant person with PAH deficiency can expose the fetus to high phenylalanine through the placenta. This can cause maternal PKU syndrome, including poor fetal growth, microcephaly, intellectual disability, congenital heart defects, and other birth defects. The fetus may be genetically unaffected and still be harmed by maternal hyperphenylalaninemia.

Preconception control is therefore essential. The metabolic team usually works toward the pregnancy target before conception and monitors levels frequently throughout pregnancy. The partner’s PAH carrier result affects whether the fetus could inherit PAH deficiency, but it does not change the need for maternal metabolic control.

Ongoing care

People diagnosed through newborn screening need lifelong access to metabolic care. Follow-up can include phenylalanine and tyrosine monitoring, nutritional assessment, growth, bone health, vitamin and mineral status, neuropsychological support, mental-health care, treatment-response review, and preparation for pregnancy.

Adults who stopped treatment should not assume that early childhood therapy permanently removed all risk from high phenylalanine. Returning to a metabolic clinic can improve concentration, mood, executive function, or neurologic symptoms in some people, even though established intellectual disability from late diagnosis may not reverse.

Families should keep the original report with both PAH variants and transcript details. Variant classifications may be updated, and laboratories differ in how they name older variants. A periodic genetics review is useful when the report contains a VUS, only one variant was found, or a new therapy depends on genotype.

Urgent evaluation is warranted for a newborn with a reported critical screen, a pregnant person with sustained phenylalanine above the treatment team’s target, seizures, marked neurologic change, severe vomiting with inability to take prescribed formula, or signs of serious nutritional deficiency. Day-to-day dietary changes should be made with the metabolic team rather than from the genetic report alone.

Preparing for illness, transitions, and future reinterpretation

A PAH result remains relevant throughout life, but the practical questions change. During fever, infection, surgery, or prolonged poor intake, the body may break down its own protein and phenylalanine can rise even when the usual diet has not changed. Families should have a written sick-day plan from the metabolic clinic, including when to check a blood spot, how to maintain prescribed medical food and fluids, and when vomiting or reduced intake requires urgent assessment. Home dried-blood-spot testing is used to monitor phenylalanine; it is not a substitute for the DNA sample used to establish genotype.

Transitions also deserve planning. Adolescents moving to adult care need access to medical food, medication review, laboratory monitoring, and counseling about pregnancy before it is needed. A person who has been stable for years may still need closer monitoring during major dietary change, weight loss, pregnancy planning, or a switch between therapies. Genotype can help estimate residual enzyme activity or possible responsiveness to a treatment, but it should not be used by itself to relax monitoring. Current phenylalanine values, nutrition, symptoms, adherence, and treatment response remain more important for day-to-day decisions.

Keep copies of the newborn screen, confirmatory biochemical results, and the complete molecular report. Older reports may use legacy PAH variant names, a different transcript, or an interpretation that has since changed. When care transfers between centers, the receiving laboratory or genetics team may need to translate the old notation into current HGVS terminology and confirm whether the two variants were shown to be on opposite copies of the gene. Reanalysis is especially useful when only one pathogenic variant was identified, a VUS remains unresolved, or the clinical and biochemical findings do not fit the original molecular conclusion.

References

• Phenylalanine Hydroxylase Deficiency 2025 (Review)
• Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) 2025 (Guideline)
• European guidelines on diagnosis and treatment of phenylketonuria: First revision 2025 (Guideline)
• Genetic etiology and clinical challenges of phenylketonuria 2022 (Review)
• Phenylketonuria 2021 (Review)

Disclaimer

This article provides general information and does not replace care from a metabolic geneticist, dietitian, obstetric specialist, or genetic counselor. Phenylalanine targets, treatment options, and monitoring schedules must be individualized, and genetic findings should be interpreted with biochemical results. An abnormal newborn screen or poorly controlled phenylalanine during pregnancy requires prompt specialist follow-up.